Can we improve protocols in clinical practice?

Can we improve protocols in clinical practice?

The association of biofilms with multi-drug resistance has highlighted the need for further understanding of biofilms and for anti-biofilm strategies. In a satellite symposium sponsored by Heraeus Medical at the 35th Annual Meeting of the European Bone and Joint Infection Society, the latest knowledge of biofilms and local methods of overcoming the challenge of infection in clinical practice was discussed.

Biofilm-related implant malfunction

In orthopaedics, bacteria may colonise a surface for months or years but remain undetected until they trigger an immune response and signs of infection. During this time, there may be low-grade infection, with symptoms such as persistent pain, stiffness, lack of range-of-movement, fibrosis, ‘aseptic’ implant loosening and non-union of fractures.

 

Biofilms and multi-drug resistance

A mature biofilm can form within 24 hours of contact with an implant and can even penetrate the surface of titanium. As the biofilm matrix is more abundant than the bacteria themselves, the biofilm must be disrupted in order to expose the bacteria to antimicrobial agents.

Multi-drug resistance may also be related to biofilm formation; for example, methicillin-resistant Staphylococcus aureus (MRSA) produces more biofilm than methicillin-susceptible S. aureus (MSSA), and therefore biofilms may magnify the cost, suffering and mortality associated with antibiotic resistance.

 

Superior outcome in hip and knee arthroplasty through antibiotic-loaded bone cements (ALAC)

In addition to the well-documented benefit of bone cements, such as PALACOS© R+G in total hip replacement (THR), registry data was presented showing that significantly fewer revisions are required when PALACOS© R+G has been used in total knee replacement surgery, compared with all other bone cements [3]. PALACOS© R+G with gentamicin also significantly outperforms plain PALACOS.

 

Significant reduction of surgical site infections (SSIs) through dual antibiotic-loaded bone cements

It is particularly important to optimise strategies for reducing peri-prosthetic joint infections (PJIs) in high-risk patients, but which bone cement best overcomes the current challenges in PJI prevention?

A quasi-randomised, double blind study was carried out, comparing the two bone cements, PALACOS© R+G and COPAL©G+C, in patients requiring hemiarthroplasty for a fractured neck of femur. There was a significant reduction in both deep and superficial SSIs with COPAL©G+C compared with PALACOS© R+G 4, explained by the previously observed high antibiotic concentrations in wound fluid [5]. Extrapolating the reduction in infection rates to the entire UK hip hemiarthroplasty population would lead to healthcare savings of over £4 million.

 

Dual antibiotic-loaded cement does not affect antibiotic resistance profiles [5]

A concern regarding the use of antibiotic-loaded bone cements is whether they cause antibiotic resistance. The study reported no significant differences in resistance between PALACOS© R+G and Copal G+C. The only cases of resistance with COPAL©G+C were to gentamicin and clindamycin, which is as expected. Resistance to other standard antibiotics remained low. Furthermore, COPAL©G+C completely eradicated infection caused by Corynebacterium species and S. aureus.

clinical practice

PALACOS R+G is superior to all other cement brands in the NJR

 

 

References

Flemming, H.-C. et al (eds) (2011) Biofilm highlights. Springer Series on Biofilms 5. Springer-Verlag, Berlin Heidelberg doi:10.1007/978-3-642-19940-0_5

Monroe, D. (2007) Looking for chinks in the armor of bacterial biofilms. PloS Biol 5(11), e307

Data on file. National Joint Registry (NJR, www.njrcentre.org.uk) data licensed to Heraeus Medical GmbH, Wehrheim, Germany

Tyas, B., Marsh, M., Molyneux, C., et al. (2016) Antibiotic resistance profiles of surgical site infections in hip hemiarthroplasty; comparing low-dose single antibiotic versus high-dose dual antibiotic impregnated cement. Abstract 59 presented at 35th Annual European Bone and Joint Infection Society (EBJIS) meeting, Oxford, UK, 1–3 September 2016

Gehrke, T., von Förster, G. and Frommelt, L. (2001) Pharmacokinetic study of a gentamicin/clindamicin bone cement used in one-stage revision arthroplasty, pp. 127–134 in Bone Cements and Cementing Technique, Springer Berlin Heidelberg

Categories: ARTICLES

Write a Comment

Your e-mail address will not be published.
Required fields are marked*